

REVIEW ARTICLE

Obstructive Sleep Apnea: Anatomical, Neuromuscular and Metabolic Factors

Spiropoulou A¹, Spyropoulos V², Spyropoulou G³, Spiropoulos K⁴

¹Oral and Maxillofacial Surgery Resident, Medical School, Attikon Hospital, National and Kapodistrian University of Athens, Greece.

²General Surgery Resident, Medical School, University Hospital of Patras, Greece.

³School of Medicine, University of Patras, Rio, Patras, Greece.

⁴Professor Emeritus of Pulmonology Medicine, University of Patras, Greece.

Received: 12 August 2026 Accepted: 27 August 2026 Published: 31 August 2026

Corresponding Author: Spiropoulou A, Oral and Maxillofacial Surgery Resident, Attikon University Hospital, National and Kapodistrian University of Athens, Greece.

Abstract

Obstructive sleep apnea (OSA) is one of the most prevalent sleep-related breathing disorders, characterized by recurrent episodes of partial or complete upper airway obstruction during sleep. These events result in intermittent hypoxia, hypercapnia, and sleep fragmentation, contributing to significant cardiovascular and metabolic morbidity.

The pathophysiology of OSA is multifactorial and involves a complex interaction between anatomical susceptibility, impaired neuromuscular control of the upper airway, ventilatory control instability, and metabolic dysfunction. Obesity, insulin resistance, and hormonal alterations play a central role in disease development and progression.

This review aims to provide a comprehensive overview of the anatomical, neuromuscular, and metabolic mechanisms underlying OSA, with emphasis on their interaction and clinical implications.

Keywords: Obstructive Sleep Apnea, Upper Airway, Obesity, Insulin Resistance, Neuromuscular Control.

1. Introduction

Obstructive sleep apnea (OSA) represents a major public health concern with a steadily increasing prevalence worldwide, largely driven by the obesity epidemic^{1,2}. It is estimated that moderate-to-severe OSA affects approximately 20–30% of the adult population².

OSA is characterized by recurrent episodes of apnea and hypopnea during sleep, leading to intermittent hypoxemia, hypercapnia, and sleep fragmentation. These disturbances result in activation of the sympathetic nervous system, oxidative stress, endothelial dysfunction, and systemic inflammation^{3–5}. Consequently, OSA is strongly associated with cardiovascular diseases, metabolic disorders, and increased mortality⁵.

Current understanding conceptualizes OSA as a disorder resulting from the interaction of four key pathophysiological traits: upper airway anatomical compromise, impaired neuromuscular responsiveness, ventilatory control instability (loop gain), and low arousal threshold⁶.

2. Anatomical Factors

2.1 Craniofacial Abnormalities

Craniofacial structural abnormalities such as micrognathia and retrognathia reduce the posterior airway space and predispose to upper airway collapse⁷. Posterior displacement of the tongue narrows the oropharyngeal lumen, especially in the supine position.

Citation: Spiropoulou A, Spyropoulos V, Spyropoulou G, *et al.* Obstructive Sleep Apnea: Anatomical, Neuromuscular and Metabolic Factors. Archives of Pulmonology and Respiratory Medicine. 2026;9(1):16-18.

©The Author(s) 2026. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

2.2 Soft Tissue Enlargement and Fat Deposition

Enlargement of the soft palate, uvula, and tonsils contributes to airway narrowing⁸. In obesity, fat deposition in the parapharyngeal region further increases airway collapsibility⁹.

2.3 Upper Airway Mechanics

The pharynx is a compliant structure lacking rigid support. Airway patency depends on the balance between intraluminal and surrounding tissue pressures. During inspiration, negative pressure promotes collapse in susceptible individuals⁶.

3. Neuromuscular Mechanisms

Upper airway patency is maintained by pharyngeal dilator muscles, particularly the genioglossus¹⁰. During sleep, especially REM sleep, neuromuscular tone decreases significantly¹¹.

In OSA patients, impaired reflex activation of these muscles in response to negative pressure contributes to airway instability¹². Increased loop gain further promotes ventilatory instability and cyclical breathing⁶.

4. Imaging and Diagnostic Approaches

Computed tomography (CT) and magnetic resonance imaging (MRI) are useful for evaluating upper airway anatomy¹³.

Drug-induced sleep endoscopy (DISE) allows real-time assessment of airway collapse under sedation¹⁴.

Ultrasound elastography is an emerging tool for evaluating tissue stiffness and may correlate with disease severity¹⁵.

5. Metabolic and Endocrine Factors

5.1 Obesity

Obesity is the strongest risk factor for OSA, increasing prevalence up to tenfold^{2,16}. Fat accumulation in the neck narrows the airway, while central obesity reduces lung volumes¹⁶.

5.2 Insulin Resistance and Diabetes

Intermittent hypoxia induces inflammatory pathways and insulin resistance¹⁷. The relationship between OSA and type 2 diabetes is bidirectional¹⁸.

5.3 Hormonal Dysregulation

OSA is associated with altered appetite regulation, including increased ghrelin and reduced leptin sensitivity¹⁹.

Hypothyroidism may further worsen OSA via reduced metabolic rate and neuromuscular tone²⁰.

6. Age and Sex Differences

OSA prevalence increases with age due to structural and neuromuscular changes²¹.

It is more common in men, but the difference decreases after menopause, suggesting hormonal protection in females²².

7. Systemic Consequences

OSA is strongly associated with hypertension, coronary artery disease, stroke, and heart failure^{5,23}.

Chronic intermittent hypoxia and sympathetic activation are key mechanisms.

OSA is also linked to cognitive impairment, depression, and reduced quality of life²⁴.

8. Conclusion

Obstructive sleep apnea is a complex disorder involving anatomical, neuromuscular, and metabolic mechanisms. Understanding these interactions is essential for accurate diagnosis and individualized therapy.

Early intervention, particularly targeting obesity, may significantly improve outcomes.

9. References

1. Jordan AS, McSharry DG, Malhotra A. Adult obstructive sleep apnoea. *Lancet*. 2014;384:736–747.
2. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing. *Am J Epidemiol*. 2013;177:1006–1014.
3. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea. *Am J Respir Crit Care Med*. 2002;165:1217–1239.
4. Punjabi NM. The epidemiology of adult obstructive sleep apnea. *Proc Am Thorac Soc*. 2008;5:136–143.
5. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, et al. Sleep apnea and cardiovascular disease. *Circulation*. 2008;118:1080–1111.
6. Eckert DJ, Malhotra A. Pathophysiology of adult obstructive sleep apnea. *Am J Respir Crit Care Med*. 2013;188:1442–1451.
7. Schwab RJ. Upper airway imaging in sleep apnea. *Clin Chest Med*. 1998;19:33–54.
8. Strollo PJ Jr, Rogers RM. Obstructive sleep apnea. *N Engl J Med*. 1996;334:99–104.

9. Shelton KE, Woodson H, Gay S, Suratt PM. Pharyngeal fat in obstructive sleep apnea. *Am Rev Respir Dis.* 1993;148:462–466.
10. Remmers JE, deGroot WJ, Sauerland EK, Anch AM. Pathogenesis of upper airway occlusion during sleep. *J Appl Physiol.* 1978;44:931–938.
11. Malhotra A, White DP. Obstructive sleep apnoea. *Lancet.* 2002;360:237–245.
12. Younes M. Role of arousal in respiratory instability. *J Appl Physiol.* 2004;96:1237–1245.
13. Schwab RJ, et al. Identification of upper airway anatomic risk factors. *Am J Respir Crit Care Med.* 2003;168:522–530.
14. Vroegop AV, et al. Drug-induced sleep endoscopy. *Sleep.* 2014;37:1193–1200.
15. Isono S. Collapsibility of the upper airway. *Sleep Med Rev.* 2012;16:443–451.
16. Foster GD, et al. Obstructive sleep apnea among obese patients. *Diabetes Care.* 2009;32:1017–1019.
17. Tasali E, Ip MS. Obstructive sleep apnea and metabolic dysfunction. *Proc Am Thorac Soc.* 2008;5:207–217.
18. Ip MS, et al. Insulin resistance in OSA. *Am J Respir Crit Care Med.* 2002;165:670–676.
19. Spiegel K, Tasali E, Penev P, Van Cauter E. Sleep loss and metabolic regulation. *Ann Intern Med.* 2004;141:846–850.
20. Lin CC, et al. Hypothyroidism and sleep apnea. *Chest.* 1992;102:1666–1670.
21. Bixler EO, et al. Age effects on sleep apnea. *Am J Respir Crit Care Med.* 2001;163:608–613.
22. Young T, et al. Gender differences in OSA. *Sleep.* 2008;31:1301–1308.
23. Marin JM, et al. Cardiovascular outcomes in OSA. *Lancet.* 2005;365:1046–1053.
24. Lim DC, Pack AI. Neurocognitive effects of OSA. *Sleep Med Rev.* 2017;31:45–58.